Page last updated: 2024-08-24

venlafaxine hydrochloride and Central Nervous System Diseases

venlafaxine hydrochloride has been researched along with Central Nervous System Diseases in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Arnecke, B; Guidry, JR; Heisler, MA1
Mekler, G; Woggon, B1
Diamond, ML; Diamond, S; Erdemoglu, AK; Freitag, FG; Pepper, BJ; Urban, GJ1
Anand, VS; Dewan, MJ1

Other Studies

4 other study(ies) available for venlafaxine hydrochloride and Central Nervous System Diseases

ArticleYear
Serotonin syndrome induced by administration of venlafaxine and phenelzine.
    The Annals of pharmacotherapy, 1996, Volume: 30, Issue:1

    Topics: Antidepressive Agents; Central Nervous System Diseases; Cyclohexanols; Depressive Disorder; Humans; Male; Middle Aged; Phenelzine; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Agents; Syndrome; Venlafaxine Hydrochloride

1996
A case of serotonin syndrome caused by venlafaxine and lithium.
    Pharmacopsychiatry, 1997, Volume: 30, Issue:6

    Topics: Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Disorder; Central Nervous System Diseases; Cyclohexanols; Drug Interactions; Female; Humans; Lithium Compounds; Middle Aged; Selective Serotonin Reuptake Inhibitors; Syndrome; Venlafaxine Hydrochloride

1997
Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports.
    Neurology, 1998, Volume: 51, Issue:1

    Topics: Adult; Central Nervous System Diseases; Cyclohexanols; Drug Interactions; Female; Humans; Male; Middle Aged; Migraine Disorders; Monoamine Oxidase Inhibitors; Phenelzine; Selective Serotonin Reuptake Inhibitors; Serotonin; Venlafaxine Hydrochloride

1998
Evaluating the tolerability of the newer antidepressants.
    The Journal of nervous and mental disease, 1999, Volume: 187, Issue:2

    Topics: Antidepressive Agents; Bupropion; Central Nervous System Diseases; Citalopram; Cyclohexanols; Delayed-Action Preparations; Drug Information Services; Fluvoxamine; Gastrointestinal Diseases; Guidelines as Topic; Humans; Incidence; Paroxetine; Piperazines; Placebos; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Dysfunctions, Psychological; Triazoles; United States; United States Agency for Healthcare Research and Quality; Venlafaxine Hydrochloride

1999